Clinical pharmacokinetics of urapidil.
Urapidil is a selective alpha 1-adrenoceptor antagonist with central antihypertensive action which is increasingly used in the treatment of hypertension. Urapidil is readily absorbed, is subject to moderate first-pass metabolism and is eliminated primarily as metabolites of much lower antihypertensive activity than the parent drug. The influences of age, renal and hepatic disease on the disposition of urapidil are reviewed. Studies on the relationship between pharmacodynamics and pharmacokinetics show that the optimum use of urapidil in clinical practice depends on an understanding of the pharmacokinetic properties of the drug.
Kirsten
R
R
Department of Clinical Pharmacology, University of Frankfurt.
Nelson
K
K
Steinijans
V W
VW
Zech
K
K
Haerlin
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D004077:Digoxin; D004347:Drug Interactions; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000378:metabolism; D007674:Kidney Diseases / Q000188:drug therapy / Q000378:metabolism; D008107:Liver Diseases / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use
D010879:Piperazines; D004077:Digoxin; C015568:urapidil